A client suffering from depression presents to the healthcare setting for pharmacologic treatment. Which of the following medications would be considered the first-line treatment for depression?
risperidone (Risperdal)
haloperidol (Haldol)
paroxetine (Paxil)
clozapine (Clozaril)
The Correct Answer is C
A. Risperidone is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder, not first-line treatment for depression.
B. Haloperidol is a typical antipsychotic used mainly for acute psychosis and agitation, not for treating depression.
C. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that is widely recognized as a first-line treatment for depression due to its efficacy and relatively favorable side effect profile.
D. Clozapine is an atypical antipsychotic reserved for treatment-resistant schizophrenia and is not indicated for the treatment of depression.
Free Nursing Test Bank
- Free Pharmacology Quiz 1
- Free Medical-Surgical Quiz 2
- Free Fundamentals Quiz 3
- Free Maternal-Newborn Quiz 4
- Free Anatomy and Physiology Quiz 5
- Free Obstetrics and Pediatrics Quiz 6
- Free Fluid and Electrolytes Quiz 7
- Free Community Health Quiz 8
- Free Promoting Health across the Lifespan Quiz 9
- Free Multidimensional Care Quiz 10
View Related questions
Correct Answer is C
Explanation
A. Allopurinol is a xanthine oxidase inhibitor used for chronic gout management and prevention, not for acute attacks.
B. Febuxostat is also used for chronic management of gout and not effective for immediate relief of an acute attack.
C. Colchicine is indicated for the treatment of acute gout flares as it helps reduce inflammation and pain associated with gout attacks.
D. Physostigmine is an antidote for anticholinergic toxicity and has no role in treating gout.
Correct Answer is B
Explanation
A. Topical ointment has a slower onset as it must be absorbed through the skin before it can exert its effects.
B. Sublingual nitroglycerin provides rapid relief of angina symptoms because it is absorbed quickly into the bloodstream through the mucous membranes in the mouth, allowing for an immediate effect.
C. Transdermal patches release nitroglycerin slowly over time, leading to a delayed onset of action.
D. Sustained-release formulations are designed for prolonged effects rather than rapid onset, making them slower to take effect compared to sublingual administration.